FDA-IMS Joint Workshop 
Virtual Platform Access
The virtual platform is now available at this link.

Existing Registrants: Log in to the platform with your email address; your password is your registration ID. If you are unable to locate your registration ID, please click the Contact Us button to the right on the virtual platform log in page.

New Registrants: Click on the above virtual platform link. Enter your email address. You will then be prompted to create an account. After finishing your profile, you will immediately be granted full access to the virtual platform.
Outcomes for patients with multiple myeloma have improved with approval of several therapies. Despite this, MM remains incurable. Recent results have also highlighted the heterogeneity in outcomes in patients with multiple myeloma. Improved understanding of the clinical and disease specific prognostic factors and the availability of multiple classes of therapies has necessitated discussions on patient populations for evaluation in clinical trials of novel therapies. Additionally, as new therapies are moved into earlier lines, it is important to evaluate the appropriateness of the control arms for clinical trials.

This workshop is intended to discuss disease setting considerations in MM, with a focus on defining patient populations for enrollment onto clinical trials for MM. This meeting will bring together representatives from the physician community, patients, pharmaceutical industry and regulatory scientists.

Goals and Objectives
- Discuss eligibility criteria for MM clinical trials in different disease settings
- Discuss considerations in defining patient populations
- Review common goals and methods for clinical trial conduct
Registration is complimentary
IN PERSON Location
The Hyatt Regency Bethesda
Room: Regency Ballroom, Ballroom Level
One Bethesda Metro Center
Bethesda, MD 20814
February 22, 2024

Processing Registration...